The role of gutmicrobiota composition, epigenetics and autoimmunity in the development and treatment of vasculitis; the VASKIR biobank
- Conditions
- vasculitisblood vessel inflammation100038161002914910047066
- Registration Number
- NL-OMON51405
- Lead Sponsor
- Amsterdam UMC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 500
In order to be eligible to participate in this study, a subject must meet all
of the following criteria:
• All individuals with vasculitis visiting the outpatient clinic of Amsterdam
UMC region are potentially eligible if they are >18 years old
• Vasculitis diagnosis is made by clinician. Vasculitis subtype will be
recorded along with the presence of auto-antibodies at time of diagnosis and
during remission (where applicable, e.g., in the case of AAV)
A potential subject who meets any of the following criteria will be excluded
from participation in this study:
• Active infection at the time of inclusion (not to influence immune-cell
function)
• Unwillingness to donate feces, urine and/or blood
• Inability to provide informed consent based on cognitive function, language
barrier or other reasons
• Absence of large bowel (i.e., colostomy)
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Primary: Gut microbiota (oral and fecal) and nasal microbiota composition in<br /><br>relation to autoimmunity status (antibodies and HLA subtype) and circulating<br /><br>immune cell (functional) assays in vasculitis patients</p><br>
- Secondary Outcome Measures
Name Time Method